Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 1/20 | 0.42 |
| ▸ | DHFR | P00374 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.34 |
| ▸ | TUBB | P07437 | 1/20 | 0.34 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.34 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.34 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.34 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.34 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.34 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.34 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.34 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.34 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.34 |
| ▸ | TUBA1C | Q9BQE3 | 1/20 | 0.34 |
| ▸ | TUBB6 | Q9BUF5 | 1/20 | 0.34 |
| ▸ | TUBB2B | Q9BVA1 | 1/20 | 0.34 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8984097 | 0.79 | KDM4E (0.36) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29407710 | 0.74 | ADORA2A (0.49) | MEN1CYP1A2KMT2AHSD17B10 | |
| SCHEMBL30616827 | 0.71 | KDM4E (0.31) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL29407640 | 0.70 | PI4KA (0.42) | KDM4EMEN1ALDH1A1HPGDTSHR | |
| SCHEMBL18305671 | 0.66 | DHFR (0.46) | DHFR | |
| SCHEMBL2042259 | 0.65 | HSP90AA1 (0.41) | DHFRALDH1A1 | |
| SCHEMBL3705558 | 0.65 | DCPS (0.47) | DCPSDHFRALDH1A1CYP1A2HPGD | |
| SCHEMBL899214 | 0.62 | NCF1 (0.43) | IDO1 | |
| SCHEMBL24174730 | 0.62 | NOS3 (0.38) | KDM4ETUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4439756 | 0.61 | KDM4E (0.34) | KDM4ETUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-06-11 | — | — | US | disclosed |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2020-05-19 | — | — | US | disclosed |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-01-21 | — | — | US | disclosed |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2019-08-08 | — | — | US | disclosed |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2019-07-11 | — | — | US | disclosed |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2019-03-26 | — | — | US | disclosed |
| US-10208051-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2019-02-19 | — | — | US | disclosed |
| US-20180162863-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2018-06-14 | — | — | US | disclosed |
| US-9896455-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2018-02-20 | — | — | US | disclosed |
| US-7960400-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2011-06-14 | — | — | US | disclosed |
| EP-2200437-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | Duquesne University of the Holy Ghost (US) | 2010-06-30 | — | — | EP | disclosed |
| US-20100105757-A1 | TREATMENT AND INHIBITION OF DISEASE CONDITIONS USING FLEXIBLE HETEROAROTINOIDS | BENBROOK DORIS M | 2010-04-29 | — | — | US | disclosed |
| US-7612107-B2 | Such as cancer, diabetes, hemophilia, liver disease, diseases involving human aldehyde dehydrogenase 2, polycystic kidney disease, lysosomal storage diseases, high cholesterol, obesity, high triglycerides, glycoprotein metabolism, and angiogenesis | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST | 2009-03-05 | — | — | US | disclosed |
| WO-2009029473-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20070238742-A1 | METHODS OF PREPARATION AND RESOLUTION OF E/Z ISOMERS OF VINYLFURO[2,3-D]PYRIMIDINE AND THEIR BIOLOGICAL ACTIVITIES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-10-11 | — | — | US | disclosed |
| US-20060281806-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA, THE | 2006-12-14 | — | — | US | disclosed |
| US-20060252817-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA, THE | 2006-11-09 | — | — | US | disclosed |
| WO-2006113627-A2 | TREATMENT AND INHIBITION OF DISEASE CONDITIONS USING FLEXIBLE HETEROAROTIONIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162863-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | DCPS 374/4885DHFR 1/4885KDM4E 3154/4885 |
| US-20070238742-A1 | METHODS OF PREPARATION AND RESOLUTION OF E/Z ISOMERS OF VINYLFURO[2,3-D]PYRIMIDINE AND THEIR BIOLOGICAL ACTIVITIES AND RELATED COMPOSITIONS AND METHODS OF TREATMENT | FOLR2, FOLR1, DHFR | DCPS 713/4885DHFR 3/4885KDM4E 1081/4885 |
| US-20090062318-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | DCPS 374/4885DHFR 1/4885KDM4E 3154/4885 |
| US-20200181152-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | FOLR1, DHFR, TUBB3 | DCPS 511/4885DHFR 2/4885KDM4E 3095/4885 |
| US-20100105757-A1 | TREATMENT AND INHIBITION OF DISEASE CONDITIONS USING FLEXIBLE HETEROAROTINOIDS | HSD17B4, HSD17B14, MAN2B1 | DCPS 2437/4885DHFR 806/4885KDM4E 3810/4885 |
| US-20190241571-A1 | Cyclopenta[d]pyrimidines And Substituted Cyclopenta[d]pyrimidines As Antitubulin and Microtubule Targeting Agents, Monocyclic Pyrimidines As Tubulin Inhibitors, And Pyrrolopyrimidines As Targeted Antifolates And Tubulin and Multiple Receptor Tyrosine Kinase Inhibition And Antitumor Agents | TUBB, TUBB1, TUBA1C | DCPS 807/4885DHFR 8/4885KDM4E 3565/4885 |
| US-10239880-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | FOLR1, TUBB1, TUBA1C | DCPS 648/4885DHFR 4/4885KDM4E 2794/4885 |
| US-10208051-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DHFR, TK1, TYMS | DCPS 374/4885DHFR 1/4885KDM4E 3154/4885 |
| US-20060281806-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | HSD17B4, HSD17B14, MAN2B1 | DCPS 2437/4885DHFR 806/4885KDM4E 3810/4885 |
| US-20060252817-A1 | Treatment and inhibition of disease conditions using flexible heteroarotinoids | HSD17B14, HSD17B4, PNLIP | DCPS 2483/4885DHFR 463/4885KDM4E 3563/4885 |
| US-11124520-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibitor and antitumor agents | FOLR1, DHFR, TUBB3 | DCPS 528/4885DHFR 2/4885KDM4E 3019/4885 |
| US-20190211019-A1 | TRICYCLIC COMPOUNDS HAVING CYTOSTATIC AND/OR CYTOTOXIC ACTIVITY AND METHODS OF USE THEREOF | DHFR, TK1, TYMS | DCPS 374/4885DHFR 1/4885KDM4E 3154/4885 |
| US-10538527-B2 | Cyclopenta[d]pyrimidines and substituted cyclopenta[d]pyrimidines as antitubulin and microtubule targeting agents, monocyclic pyrimidines as tubulin inhibitors, and pyrrolopyrimidines as targeted antifolates and tubulin and multiple receptor tyrosine kinase inhibition and antitumor agents | TUBB, TUBB1, TUBA1C | DCPS 807/4885DHFR 8/4885KDM4E 3565/4885 |
| US-10654858-B2 | Tricyclic compounds having cytostatic and/or cytotoxic activity and methods of use thereof | DHFR, TK1, TYMS | DCPS 374/4885DHFR 1/4885KDM4E 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.